cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28070811
title: A diagnostic signatures for intervertebral disc degeneration using TNFAIP6 and COL6A2 based on single-cell RNA-seq and bulk RNA-seq analyses

description: Intervertebral disc degeneration (IVDD) is a prevalent degenerative condition associated with a high incidence rate of low back pain and disability. This study aimed to identify potential biomarkers and signaling pathways associated with IVDD. Biomarkers were discerned through bulk-RNA and single-cell RNA sequencing (scRNA-Seq) investigations of IVDD cases from the Gene Expression Omnibus (GEO) database. Following this, two central genes were identified. Furthermore, gene set enrichment analysis (GSEA) and receiver operating characteristic (ROC) curve analysis were conducted. The transcriptional factor (TF) derived from nucleus pulposus (NP) cells was examined through the DoRothEA R package. RT-qPCR and IHC techniques were employed to confirm the expression of the two hub genes and their associated genes in tissue samples. The proteins Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) and collagen VI-α2 (COL6A2) were frequently analyzed using a combination of DEGs from datasets GSE70362, GSE124272, and scRNA-seq. Examination of gene expression across multiple datasets indicated significant differences in TNFAIP6 and COL6A2 levels in IVDD compared to control or normal groups (<i>p</i> &lt; 0.05). These two central genes demonstrated strong diagnostic utility in the training cohort and reliable predictive value in the validation datasets. Our study verified the potential role of ZEB2 as a TF in regulating two key genes associated with IVDD. Furthermore, qPCR and IHC confirmed elevated expression levels of the hub genes and transcription factor. We identified biomarkers, specifically TNFAIP6 and COL6A2, that have the potential to predict disease activity and aid in the diagnosis of IVDD.
DOI: 10.6084/m9.figshare.28070811.v1
title: A diagnostic signatures for intervertebral disc degeneration using TNFAIP6 and COL6A2 based on single-cell RNA-seq and bulk RNA-seq analyses

description: Intervertebral disc degeneration (IVDD) is a prevalent degenerative condition associated with a high incidence rate of low back pain and disability. This study aimed to identify potential biomarkers and signaling pathways associated with IVDD. Biomarkers were discerned through bulk-RNA and single-cell RNA sequencing (scRNA-Seq) investigations of IVDD cases from the Gene Expression Omnibus (GEO) database. Following this, two central genes were identified. Furthermore, gene set enrichment analysis (GSEA) and receiver operating characteristic (ROC) curve analysis were conducted. The transcriptional factor (TF) derived from nucleus pulposus (NP) cells was examined through the DoRothEA R package. RT-qPCR and IHC techniques were employed to confirm the expression of the two hub genes and their associated genes in tissue samples. The proteins Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) and collagen VI-α2 (COL6A2) were frequently analyzed using a combination of DEGs from datasets GSE70362, GSE124272, and scRNA-seq. Examination of gene expression across multiple datasets indicated significant differences in TNFAIP6 and COL6A2 levels in IVDD compared to control or normal groups (<i>p</i> &lt; 0.05). These two central genes demonstrated strong diagnostic utility in the training cohort and reliable predictive value in the validation datasets. Our study verified the potential role of ZEB2 as a TF in regulating two key genes associated with IVDD. Furthermore, qPCR and IHC confirmed elevated expression levels of the hub genes and transcription factor. We identified biomarkers, specifically TNFAIP6 and COL6A2, that have the potential to predict disease activity and aid in the diagnosis of IVDD.
DOI: 10.6084/m9.figshare.28382262
title: The reliability and validity of the Swedish translation of the Vertigo Symptom Scale – short form in a cohort with acute vestibular syndrome

description: The Vertigo Symptom Scale – short form (VSS–SF) is commonly used to measure dizziness and vertigo over the past month. This study aimed to (1) adapt the VSS–SF for the Swedish population and assess its psychometric properties, and (2) develop a modified version for measuring symptoms in the acute phase of acute vestibular syndrome (AVS). The VSS–SF was translated into Swedish and adapted cross-culturally. Its psychometric properties were evaluated in 86 AVS patients, both in the acute stage (1–7 days from symptom onset) with a modified acute version, and after six weeks of vestibular rehabilitation using the standard VSS–SF. Factor structure, convergent and discriminant validity, and internal consistency were analyzed. Test-retest reliability was assessed at six weeks. Participants were also evaluated with the Dizziness Handicap Inventory (DHI) and balance tests. Controls included 54 healthy participants. Exploratory factor analysis revealed a two-factor structure for both versions, corresponding to vertigo-balance (VSS–V) and autonomic-anxiety (VSS–A) subscales. Both versions demonstrated strong factor structures with adequate loadings. Internal consistency was high for the standard version (Cronbach’s alpha 0.76 to 0.87) and for the total and VSS–V subscale of the acute version (0.82 and 0.85, respectively), but poor for the acute VSS–A subscale (0.50). Convergent validity was supported by Spearman’s rank correlations. The discriminative ability was excellent for the acute VSS–SF and VSS–V (AUC 0.98 and 0.99), and acceptable for VSS–A (AUC 0.77). After six weeks, discriminative ability decreased but remained above 0.5. Test-retest reliability at six weeks was excellent for all scales (ICC 0.94, 0.93, and 0.93 for VSS–SF, VSS–V, and VSS–A). The VSS–SF was successfully adapted for the Swedish population, including an acute version for early dizziness assessment. Both versions confirmed a robust two-factor structure, with the acute version showing excellent early discriminative ability, particularly for the vertigo-balance dimension. However, the autonomic-anxiety subscale showed weaker psychometric properties, suggesting limited suitability for AVS patients. The adapted scales show promise for clinical use in diagnosing and evaluating dizziness and vertigo in the Swedish population. Clinicaltrials.gov Identifier NCT05056324, September 24, 2021. https://clinicaltrials.gov/ct2/show/NCT05056324
DOI: 10.6084/m9.figshare.28382262.v1
title: The reliability and validity of the Swedish translation of the Vertigo Symptom Scale – short form in a cohort with acute vestibular syndrome

description: The Vertigo Symptom Scale – short form (VSS–SF) is commonly used to measure dizziness and vertigo over the past month. This study aimed to (1) adapt the VSS–SF for the Swedish population and assess its psychometric properties, and (2) develop a modified version for measuring symptoms in the acute phase of acute vestibular syndrome (AVS). The VSS–SF was translated into Swedish and adapted cross-culturally. Its psychometric properties were evaluated in 86 AVS patients, both in the acute stage (1–7 days from symptom onset) with a modified acute version, and after six weeks of vestibular rehabilitation using the standard VSS–SF. Factor structure, convergent and discriminant validity, and internal consistency were analyzed. Test-retest reliability was assessed at six weeks. Participants were also evaluated with the Dizziness Handicap Inventory (DHI) and balance tests. Controls included 54 healthy participants. Exploratory factor analysis revealed a two-factor structure for both versions, corresponding to vertigo-balance (VSS–V) and autonomic-anxiety (VSS–A) subscales. Both versions demonstrated strong factor structures with adequate loadings. Internal consistency was high for the standard version (Cronbach’s alpha 0.76 to 0.87) and for the total and VSS–V subscale of the acute version (0.82 and 0.85, respectively), but poor for the acute VSS–A subscale (0.50). Convergent validity was supported by Spearman’s rank correlations. The discriminative ability was excellent for the acute VSS–SF and VSS–V (AUC 0.98 and 0.99), and acceptable for VSS–A (AUC 0.77). After six weeks, discriminative ability decreased but remained above 0.5. Test-retest reliability at six weeks was excellent for all scales (ICC 0.94, 0.93, and 0.93 for VSS–SF, VSS–V, and VSS–A). The VSS–SF was successfully adapted for the Swedish population, including an acute version for early dizziness assessment. Both versions confirmed a robust two-factor structure, with the acute version showing excellent early discriminative ability, particularly for the vertigo-balance dimension. However, the autonomic-anxiety subscale showed weaker psychometric properties, suggesting limited suitability for AVS patients. The adapted scales show promise for clinical use in diagnosing and evaluating dizziness and vertigo in the Swedish population. Clinicaltrials.gov Identifier NCT05056324, September 24, 2021. https://clinicaltrials.gov/ct2/show/NCT05056324
DOI: 10.15468/dl.hs84m3
title: Occurrence Download

description: A dataset containing 95 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Enneacampus kaupi"
 ]
}

 The dataset includes 95 records from 20 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003096-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2dwk9m
title: Occurrence Download

description: A dataset containing 2460 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((-71.977 5.993139, -72.047646 5.987568, -72.11654799999999 5.970993, -72.182006 5.943823, -72.242406 5.906728, -72.29625799999999 5.860624, -72.342236 5.806647, -72.379209 5.746129, -72.406268 5.680563, -72.42274999999999 5.611562, -72.428252 5.540828, -72.42264400000001 5.470102, -72.406066 5.401126, -72.37893200000001 5.335596, -72.34191 5.275126, -72.29591499999999 5.221201, -72.24208 5.175149, -72.181729 5.138101, -72.11634599999999 5.110968, -72.04754 5.094417, -71.977 5.088854, -71.90646 5.094417, -71.837654 5.110968, -71.772271 5.138101, -71.71192000000001 5.175149, -71.658085 5.221201, -71.61208999999999 5.275126, -71.575068 5.335596, -71.547934 5.401126, -71.531356 5.470102, -71.52574799999999 5.540828, -71.53125 5.611562, -71.547732 5.680563, -71.574791 5.746129, -71.61176399999999 5.806647, -71.657742 5.860624, -71.71159400000001 5.906728, -71.77199400000001 5.943823, -71.837452 5.970993, -71.90635399999999 5.987568, -71.977 5.993139))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 2460 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003097-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30246611
title: Burden and forecast of colorectal cancer in the selected East Asian countries (1990–2036): a systematic analysis based on the global burden of disease study 2021

description: Colorectal cancer (CRC) is a leading global cause of cancer morbidity and mortality, yet how its burden has shifted during rapid demographic and lifestyle change in East Asia remains poorly characterized. This study fills that gap by examining long‑term trends and drivers of CRC burden in the selected East Asian countries—China, Japan, North Korea, South Korea, and Mongolia—between 1990 and 2021, and by projecting future burden through 2036. We obtained data from the Global Burden of Disease (GBD) Study 2021 on CRC-related prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) in the selected countries, further assessed by age and sex. We quantified contributions of population growth, aging and epidemiological change <i>via</i> decomposition analysis, characterized temporal trends with Joinpoint and age–period–cohort analysis, and generated forecasts to 2036 using Autoregressive Integrated Moving Average and Bayesian age-period-cohort approaches. Although absolute CRC burden rose across the region—driven largely by population aging—with China exhibiting the highest numbers and Japan exhibiting the highest age‑standardized rates. Older adults bore the greatest share of burden. Decomposition and modeling indicate that demographic shifts have been the predominant force behind increasing CRC counts, and projected trends suggest the regional burden will remain substantial without targeted action. This study provides novel, region‑specific evidence that demographic aging is the principal driver of rising CRC burden in East Asia. The findings highlight an urgent need for tailored prevention, screening and resource planning focused on aging populations to alter the projected trajectory.
DOI: 10.6084/m9.figshare.30246611.v1
title: Burden and forecast of colorectal cancer in the selected East Asian countries (1990–2036): a systematic analysis based on the global burden of disease study 2021

description: Colorectal cancer (CRC) is a leading global cause of cancer morbidity and mortality, yet how its burden has shifted during rapid demographic and lifestyle change in East Asia remains poorly characterized. This study fills that gap by examining long‑term trends and drivers of CRC burden in the selected East Asian countries—China, Japan, North Korea, South Korea, and Mongolia—between 1990 and 2021, and by projecting future burden through 2036. We obtained data from the Global Burden of Disease (GBD) Study 2021 on CRC-related prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) in the selected countries, further assessed by age and sex. We quantified contributions of population growth, aging and epidemiological change <i>via</i> decomposition analysis, characterized temporal trends with Joinpoint and age–period–cohort analysis, and generated forecasts to 2036 using Autoregressive Integrated Moving Average and Bayesian age-period-cohort approaches. Although absolute CRC burden rose across the region—driven largely by population aging—with China exhibiting the highest numbers and Japan exhibiting the highest age‑standardized rates. Older adults bore the greatest share of burden. Decomposition and modeling indicate that demographic shifts have been the predominant force behind increasing CRC counts, and projected trends suggest the regional burden will remain substantial without targeted action. This study provides novel, region‑specific evidence that demographic aging is the principal driver of rising CRC burden in East Asia. The findings highlight an urgent need for tailored prevention, screening and resource planning focused on aging populations to alter the projected trajectory.
DOI: 10.6084/m9.figshare.30284519
title: Artificial intelligence for the prediction of posthepatectomy recurrence in hepatocellular carcinoma: a systematic review and meta-analysis

description: Posthepatectomy recurrence of hepatocellular carcinoma (HCC) is a major cause of poor prognosis. Accurate prediction is essential for reducing the burden of advanced disease and improving outcomes. A systematic search of the PubMed, Embase, and Cochrane Library databases was conducted from their inception to December 31, 2024. The standard quality assessment of diagnostic accuracy studies (QUADAS-2) tool was utilized to analyse the methodological quality of the included studies. Bivariate linear mixed models were used to pool diagnostic estimates, including sensitivity (Se), specificity (Sp), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Additionally, the area under the receiver operating characteristic curves (AUC) of the included studies was utilized to evaluate the diagnostic value. A total of 6665 HCC patients included in 20 studies were enrolled. The pooled Se, Sp, PLR, NLR, DOR and AUC for the overall AI-assisted diagnostic performance for postoperative HCC recurrence were 0.87 (95% CI: 0.72–0.83), 0.85 (95% CI: 0.80–0.90), 5.39 (95% CI: 3.85–7.55), 0.25 (95% CI: 0.20–0.33), 21 (95% CI: 13–35), and 0.89 (95% CI: 0.86–0.91), respectively. AI showed high accuracy in predicting the posthepatectomy recurrence of HCC and would shed light on screening and monitoring high-risk patients following liver resection for further treatment.
DOI: 10.6084/m9.figshare.30284519.v1
title: Artificial intelligence for the prediction of posthepatectomy recurrence in hepatocellular carcinoma: a systematic review and meta-analysis

description: Posthepatectomy recurrence of hepatocellular carcinoma (HCC) is a major cause of poor prognosis. Accurate prediction is essential for reducing the burden of advanced disease and improving outcomes. A systematic search of the PubMed, Embase, and Cochrane Library databases was conducted from their inception to December 31, 2024. The standard quality assessment of diagnostic accuracy studies (QUADAS-2) tool was utilized to analyse the methodological quality of the included studies. Bivariate linear mixed models were used to pool diagnostic estimates, including sensitivity (Se), specificity (Sp), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Additionally, the area under the receiver operating characteristic curves (AUC) of the included studies was utilized to evaluate the diagnostic value. A total of 6665 HCC patients included in 20 studies were enrolled. The pooled Se, Sp, PLR, NLR, DOR and AUC for the overall AI-assisted diagnostic performance for postoperative HCC recurrence were 0.87 (95% CI: 0.72–0.83), 0.85 (95% CI: 0.80–0.90), 5.39 (95% CI: 3.85–7.55), 0.25 (95% CI: 0.20–0.33), 21 (95% CI: 13–35), and 0.89 (95% CI: 0.86–0.91), respectively. AI showed high accuracy in predicting the posthepatectomy recurrence of HCC and would shed light on screening and monitoring high-risk patients following liver resection for further treatment.
DOI: 10.6084/m9.figshare.30172370
title: Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study

description: This study assessed the effectiveness and safety of patisiran in patients with V122I/T60A variant transthyretin (ATTRv) amyloidosis with polyneuropathy. These variants have been under-represented in previous trials of gene-silencing agents. This was a multicenter, phase IV study conducted at 27 sites in the USA. Patients were ≥ 18 years, diagnosed with ATTRv amyloidosis with polyneuropathy and a documented V122I or T60A variant. Patisiran-treated patients were enrolled prospectively, ambispectively, and retrospectively. The primary endpoint was the proportion of patients with a stable or improved polyneuropathy disability (PND) score at 12 months <i>vs</i>. baseline. Safety was monitored throughout the trial. Sixty-seven patients were enrolled, of whom 58 received ≥ 1 dose of patisiran. In the efficacy population, 42/45 (93.3%) patients demonstrated stable or improved PND scores from baseline to Month 12. Patients also showed stable or improved quality of life, health status, autonomic symptoms, and cardiac function <i>vs</i>. baseline. Adverse events occurred in 13/42 (31.0%) patients in the prospective and ambispective cohorts; most were mild or moderate. No deaths or cardiac hospitalizations were considered related to patisiran. Patisiran demonstrated a consistent positive effect across multiple endpoints in patients with V122I/T60A ATTRv amyloidosis, including polyneuropathy manifestations.
DOI: 10.6084/m9.figshare.30172370.v1
title: Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study

description: This study assessed the effectiveness and safety of patisiran in patients with V122I/T60A variant transthyretin (ATTRv) amyloidosis with polyneuropathy. These variants have been under-represented in previous trials of gene-silencing agents. This was a multicenter, phase IV study conducted at 27 sites in the USA. Patients were ≥ 18 years, diagnosed with ATTRv amyloidosis with polyneuropathy and a documented V122I or T60A variant. Patisiran-treated patients were enrolled prospectively, ambispectively, and retrospectively. The primary endpoint was the proportion of patients with a stable or improved polyneuropathy disability (PND) score at 12 months <i>vs</i>. baseline. Safety was monitored throughout the trial. Sixty-seven patients were enrolled, of whom 58 received ≥ 1 dose of patisiran. In the efficacy population, 42/45 (93.3%) patients demonstrated stable or improved PND scores from baseline to Month 12. Patients also showed stable or improved quality of life, health status, autonomic symptoms, and cardiac function <i>vs</i>. baseline. Adverse events occurred in 13/42 (31.0%) patients in the prospective and ambispective cohorts; most were mild or moderate. No deaths or cardiac hospitalizations were considered related to patisiran. Patisiran demonstrated a consistent positive effect across multiple endpoints in patients with V122I/T60A ATTRv amyloidosis, including polyneuropathy manifestations.